Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects

• Päätekijät: Jiuhong Zha (Tekijä), Qi Jiang (Tekijä), Betty B. Yao (Tekijä), Daniel E. Cohen (Tekijä), David C. Carter (Tekijä), Rajeev M. Menon (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Wiley, 2022-12-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract The immunosuppressive agents sirolimus and everolimus are sensitive CYP3A4 substrates with narrow therapeutic index. Ritonavir is a strong CYP3A inhibitor. A phase 1 study was conducted to evaluate the pharmacokinetics, safety, and tolerability of the co‐administration of sirolimus or evero...